MANCIA GIUSEPPE

Ruolo:
Professore emerito

Pubblicazioni

  • Mancia, G., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Kjeldsen, S., et al. (2024). Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. HYPERTENSION [10.1161/HYPERTENSIONAHA.124.22821]. Dettaglio

  • Kreutz, R., Palatini, P., Stergiou, G., Mancia, G. (2024). Orthostatic hypotension an important phenotype in the 2023 European Society of Hypertension guidelines: how to measure it?. JOURNAL OF HYPERTENSION, 42(1), 188-189 [10.1097/HJH.0000000000003618]. Dettaglio

  • Grassi, G., Kreutz, R., Mancia, G. (2024). The 2023 European Society of Hypertension guidelines for high blood pressure – What's new on diagnostic and therapeutic approaches. PHARMACOLOGICAL RESEARCH, 199(January 2024) [10.1016/j.phrs.2023.107003]. Dettaglio

  • Cuspidi, C., Facchetti, R., Quarti-Trevano, F., Dell'Oro, R., Mancia, G., Grassi, G. (2024). Cardio-Ankle Vascular Index As A Marker Of Left Ventricular Hypertrophy In Treated Hypertensives: Findings From The Pamela Study. AMERICAN JOURNAL OF HYPERTENSION [10.1093/ajh/hpae022]. Dettaglio

  • Mancia, G., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M., et al. (2024). Rationale of treatment recommendations in the 2023 ESH hypertension guidelines. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 121(March 2024), 4-8 [10.1016/j.ejim.2023.12.015]. Dettaglio

Progetti di ricerca

EU-MASCARA-Markers for Sub-Clinical Cardiovascular Risk Assessemnt
Anno: 2011
Bando: 2011-014 - HEALTH.2011.2.4.2-2
Enti finanziatori: UNIONE EUROPEA
Network Enabled Drug Design
Anno: 2009
Bando: 2009-007 - Bando Fondo per la promozione di accordi istituzionali, Bando accordi istituzionali
Integrating Genomics, clinical Research and care Hypertension
Anno: 2005
Bando: FP6-LIFESCIHEALTH Life sciences, genomics and biotechnology for health,LSH-2005-2.1.1-2 Hypertension and cardiovascular disease